KZA Media Thread, page-1858

Apr 12 2022 9:00AM CT206. EVT801, a novel selective VEGFR-3 inhibitor targeting tumor angiogenesis, started enrollment for its phase I first-in-human study
Apr 12 2022 1:30PM 3203. Cutting edge biomarkers strategy to provide early insights into activity of EVT-801, a novel selective VEGFR-3 inhibitor that targets tumor angiogenesis during the FIH clinical trial

Couple abstracts on EVT801 at AACR site but nothing I could find on Paxalisib.